Cargando…

Emerging immunotherapies for autoimmune kidney disease

Autoimmunity is a leading cause of chronic kidney disease and loss of native and transplanted kidneys. Conventional immunosuppressive therapies can be effective but are non-specific, noncurative, and risk serious side effects such as life-threatening infection and cancer. Novel therapies and targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Mary Helen, Ord, Jeffrey Robinson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605834/
https://www.ncbi.nlm.nih.gov/pubmed/30550361
http://dx.doi.org/10.1080/21645515.2018.1555569
_version_ 1783431836775481344
author Foster, Mary Helen
Ord, Jeffrey Robinson
author_facet Foster, Mary Helen
Ord, Jeffrey Robinson
author_sort Foster, Mary Helen
collection PubMed
description Autoimmunity is a leading cause of chronic kidney disease and loss of native and transplanted kidneys. Conventional immunosuppressive therapies can be effective but are non-specific, noncurative, and risk serious side effects such as life-threatening infection and cancer. Novel therapies and targeted interventions are urgently needed. In this brief review we explore diverse strategies currently in development and under consideration to interrupt underlying disease mechanisms in immune-mediated renal injury. Because autoantibodies are prominent in diagnosis and pathogenesis in multiple human glomerulopathies, we highlight several promising therapies that interfere with functions of early mediators (IgG and complement) of the effector arm and with an epicenter (the germinal center) for induction of humoral immunity.
format Online
Article
Text
id pubmed-6605834
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-66058342019-07-09 Emerging immunotherapies for autoimmune kidney disease Foster, Mary Helen Ord, Jeffrey Robinson Hum Vaccin Immunother Review Autoimmunity is a leading cause of chronic kidney disease and loss of native and transplanted kidneys. Conventional immunosuppressive therapies can be effective but are non-specific, noncurative, and risk serious side effects such as life-threatening infection and cancer. Novel therapies and targeted interventions are urgently needed. In this brief review we explore diverse strategies currently in development and under consideration to interrupt underlying disease mechanisms in immune-mediated renal injury. Because autoantibodies are prominent in diagnosis and pathogenesis in multiple human glomerulopathies, we highlight several promising therapies that interfere with functions of early mediators (IgG and complement) of the effector arm and with an epicenter (the germinal center) for induction of humoral immunity. Taylor & Francis 2019-01-16 /pmc/articles/PMC6605834/ /pubmed/30550361 http://dx.doi.org/10.1080/21645515.2018.1555569 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Foster, Mary Helen
Ord, Jeffrey Robinson
Emerging immunotherapies for autoimmune kidney disease
title Emerging immunotherapies for autoimmune kidney disease
title_full Emerging immunotherapies for autoimmune kidney disease
title_fullStr Emerging immunotherapies for autoimmune kidney disease
title_full_unstemmed Emerging immunotherapies for autoimmune kidney disease
title_short Emerging immunotherapies for autoimmune kidney disease
title_sort emerging immunotherapies for autoimmune kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605834/
https://www.ncbi.nlm.nih.gov/pubmed/30550361
http://dx.doi.org/10.1080/21645515.2018.1555569
work_keys_str_mv AT fostermaryhelen emergingimmunotherapiesforautoimmunekidneydisease
AT ordjeffreyrobinson emergingimmunotherapiesforautoimmunekidneydisease